Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06947928 · ClinicalTrials.gov registry record · Phase 2
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
A Phase 2 study of Advanced Or Metastatic Merkel Cell Carcinoma, sponsored by TuHURA Biosciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 118
- Enrollment target
- 8
- Study locations
NCT06947928 is a Phase 2 study of Advanced Or Metastatic Merkel Cell Carcinoma that is actively recruiting participants, run by TuHURA Biosciences. The registered enrollment target is 118 participants. The trial reports 8 study locations across 6 states.
The verdict
NCT06947928, a Phase 2 study of Advanced Or Metastatic Merkel Cell Carcinoma, is actively recruiting participants, sponsored by TuHURA Biosciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 118 participants
- Enrollment target
- 8
- Study locations
Study Summary
This Phase 2/3, multicenter, randomized, double-blind, placebo-controlled trial will evaluate the Objective Response Rate (ORR) of IFx-Hu2.0 as an adjunctive therapy to pembrolizumab in adult participants (≥18 years) with advanced or metastatic Merkel Cell Carcinoma. A total of 118 participants will be randomized to receive either IFx-Hu2.0 or placebo via intralesional injection in a single lesion, followed by pembrolizumab.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Placebo
- DRUG IFx-Hu2.0
Study Locations (8)
California
- USC Norris Comprehensive Cancer Center - Los Angeles
- Stanford Health Care - Skin Cancer Program - Palo Alto
- University of California San Francisco - Helen Diller Family Comprehensive Cancer Center - San Francisco
Massachusetts
- Dana-Farber Cancer Institute - Boston
New Jersey
- Atlantic Health System - Morristown
North Carolina
- East Carolina University - Greenville
Virginia
- Virginia Commonwealth University - Massey Cancer Center - Richmond
Washington
- Fred Hutchinson Cancer Research Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2025-10 |
| Est. Completion | 2032-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06947928
The ClinicalTrials.gov registry entry for NCT06947928 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TuHURA Biosciences, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Or Metastatic Merkel Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT06947928 reports 8 study locations spanning 6 distinct geographic areas - top geographies include California, Massachusetts, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06947928 about?
NCT06947928 is a clinical study titled "Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma". This Phase 2/3, multicenter, randomized, double-blind, placebo-controlled trial will evaluate the Objective Response Rate (ORR) of IFx-Hu2.0 as an adjunctive therapy to pembrolizumab in adult participants (≥18 years) with advanced or metastatic Merkel Cell Carcinoma. A total of 118 participants will...
What is the current status of trial NCT06947928?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 118 participants. The study started on 2025-10. Estimated completion is 2032-12-30.
What conditions does trial NCT06947928 study?
This clinical trial studies the following conditions: Advanced Or Metastatic Merkel Cell Carcinoma.
What interventions are being tested in trial NCT06947928?
The interventions under investigation include: Pembrolizumab (DRUG), Placebo (DRUG), IFx-Hu2.0 (DRUG).
Who is sponsoring clinical trial NCT06947928?
This trial is sponsored by TuHURA Biosciences, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06947928 being conducted?
This trial has 8 study locations across California, Massachusetts, New Jersey, North Carolina, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Or Metastatic Merkel Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.